[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Saxena A, Memauri B, Hasegawa W: Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour. J Clin Pathol; 2005 Mar;58(3):331-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour.
  • Warthin tumours (WT) and malignant lymphomas are only rarely associated, and most are examples of involvement of the lymphoid stroma of WT by a disseminated lymphoma.
  • This report describes a case where excision of a parotid mass led to the initial diagnosis of WT and small lymphocytic lymphoma (SLL).
  • The patient had stage IV A disease and is currently in chemotherapy induced complete remission.
  • [MeSH-major] Adenolymphoma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):113-9 [10631864.001]
  • [Cites] Histopathology. 1993 Mar;22(3):280-1 [8495960.001]
  • [Cites] Ear Nose Throat J. 1979 Aug;58(8):345-50 [583035.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:307-24 [583554.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2948-50 [7139585.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Hum Pathol. 1985 Apr;16(4):424-7 [3980011.001]
  • [Cites] J Pathol. 1985 Jul;146(3):167-77 [3928854.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):491-6 [3082065.001]
  • [Cites] Pathol Res Pract. 1986 Oct;181(5):615-20 [3786253.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):341-4 [2538052.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):212-5 [2184550.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):974-7 [2394439.001]
  • [Cites] Pathology. 1992 Apr;24(2):60-2 [1322520.001]
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):264-9, 272-3 [8486105.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • (PMID = 15735173.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770608
  •  go-up   go-down


2. Danilov AV, Danilova OV, Brown JR, Rabinowitz A, Klein AK, Huber BT: Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol; 2010 Dec;38(12):1167-77
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.
  • OBJECTIVE: Dipeptidyl peptidase 2 (DPP2/DPP7) is a regulator of quiescence as inhibition of DPP2 results in apoptosis of resting, but not activated lymphocytes.
  • The purpose of the present study was to investigate the prognostic value of DPP2 inhibition and the role of DPP2 in cell cycle in chronic lymphocytic leukemia (CLL).
  • The apoptotic response was correlated with B-cell receptor signaling and cell cycle and molecular prognostic factors.
  • DPP2 inhibition in those cells resulted in apoptosis accompanied by enhanced phosphorylation of Syk, degradation of p27 and p130, and upregulation of c-Myc, indicative of activation and inappropriate cell cycle entry.
  • DPP2 inhibition alone or with concomitant inhibition of heat shock protein 90 warrants investigation as a therapeutic modality in CLL.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • [Cites] Blood Rev. 2008 Jul;22(4):211-9 [18448218.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2445-55 [17982489.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5424-32 [19549911.001]
  • [Cites] Blood. 2009 Jul 30;114(5):957-64 [19414856.001]
  • [Cites] Cell Cycle. 2009 Aug;8(15):2425-34 [19556882.001]
  • [Cites] Cytometry B Clin Cytom. 2009 Nov;76(6):385-93 [19479984.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34053-8 [10567372.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):47-52 [11790554.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):354-63 [12033741.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1404-9 [12149224.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31263-9 [12070150.001]
  • [Cites] Trends Immunol. 2003 Jul;24(7):380-6 [12860529.001]
  • [Cites] Leukemia. 2004 Mar;18(3):584-8 [14712292.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Cell. 1983 Dec;35(3 Pt 2):603-10 [6606489.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Leuk Lymphoma. 1996 Dec;24(1-2):27-33 [9049959.001]
  • [Cites] Blood Rev. 1997 Sep;11(3):119-28 [9370043.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4694-700 [9616167.001]
  • [Cites] J Immunol. 1999 Sep 15;163(6):3092-9 [10477574.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):472-81 [15686454.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2036-41 [15514014.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7328-37 [16103084.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2506-12 [15972449.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):283-94 [16557260.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7158-66 [16849562.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jan 15;17(2):507-10 [17055271.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2032-9 [17038529.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3352-9 [17684154.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):837-44 [17949452.001]
  • [Cites] J Cell Biochem. 2007 Dec 15;102(6):1400-4 [17979151.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2685-92 [18048647.001]
  • [Cites] Mol Immunol. 2008 Aug;45(13):3618-23 [18555530.001]
  • (PMID = 20817072.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR045386-03; United States / NIAMS NIH HHS / AR / R01 AR045386-03; United States / NIAID NIH HHS / AI / R01 AI043469; United States / NCI NIH HHS / CA / K23 CA115682; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01CA081534; United States / NIAID NIH HHS / AI / R01AI43469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / RNA, Small Interfering; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.14.2 / dipeptidyl peptidase II
  • [Other-IDs] NLM/ NIHMS246371; NLM/ PMC2991601
  •  go-up   go-down


3. Zent CS, Kay NE: Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol; 2010 Mar;23(1):47-59
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune complications in chronic lymphocytic leukaemia (CLL).
  • Patients with B-chronic lymphocytic leukaemia /small lymphocytic lymphoma (CLL) have a 5-10% risk of developing autoimmune complications, which primarily cause cytopaenia.
  • These autoimmune cytopaenias can occur at any stage of CLL and do not have independent prognostic significance.
  • The most common autoimmune complication is autoimmune haemolytic anaemia with a lower frequency of immune thrombocytopaenia and pure red blood cell aplasia and only rarely, autoimmune granulocytopaenia (AIG).

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Am J Hematol. 1999 Jun;61(2):98-102 [10367787.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):261-2 [10444204.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):836-7 [10469479.001]
  • [Cites] Am J Med. 1955 Jun;18(6):961-89 [14376415.001]
  • [Cites] Blood. 1956 Jul;11(7):648-64 [13328945.001]
  • [Cites] Am J Hematol. 2004 Dec;77(4):413-5 [15551407.001]
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):791-4 [11309323.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2016-22 [11596014.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1092-4 [11807020.001]
  • [Cites] Am J Hematol. 2002 Apr;69(4):258-71 [11921020.001]
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2092-5 [12357362.001]
  • [Cites] Hematol J. 2002;3(6):299-301 [12522452.001]
  • [Cites] Eur J Haematol. 2003 May;70(5):319-21 [12694169.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Leukemia. 2007 Mar;21(3):511-4 [17215854.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • [Cites] Br J Haematol. 2007 Mar;136(6):800-5 [17341265.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2412-7 [18067017.001]
  • [Cites] Haematologica. 2008 Jan;93(1):151-2 [18166805.001]
  • [Cites] Blood. 2008 Jan 15;111(2):680-7 [17761830.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1110-6 [17986663.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1820-6 [18055869.001]
  • [Cites] Blood Rev. 2008 Jan;22(1):17-31 [17904259.001]
  • [Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1325-8 [18420827.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3674-83 [18714043.001]
  • [Cites] Br J Haematol. 2008 Oct;143(1):16-26 [18573111.001]
  • [Cites] Leuk Res. 2009 Mar;33(3):366-7 [18930543.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3154-60 [19096013.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):892-9 [19391041.001]
  • [Cites] Leuk Lymphoma. 2009 Jun;50(6):863-4 [19455465.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):1-8 [12949883.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):278-81 [14531909.001]
  • [Cites] Mayo Clin Proc. 2003 Nov;78(11):1340-6 [14601692.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1951-5 [14738149.001]
  • [Cites] Clin Exp Immunol. 1966 Jan;1(1):3-11 [5953036.001]
  • [Cites] Blood. 1967 Apr;29(4):Suppl:566-84 [6022294.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] J Exp Med. 1980 Dec 1;152(6):1484-96 [6969771.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):844-50 [6821851.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Autoimmun. 1988 Oct;1(5):469-81 [2473761.001]
  • [Cites] Am J Hematol. 1992 Sep;41(1):5-12 [1503099.001]
  • [Cites] Am J Med. 1992 Oct;93(4):435-40 [1415307.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1672-80 [8473510.001]
  • [Cites] Leuk Lymphoma. 1993 Jan;9(1-2):149-51 [8477195.001]
  • [Cites] Blood. 1993 May 15;81(10):2475-87 [8490163.001]
  • [Cites] Lancet. 1993 Aug 28;342(8870):555 [8102691.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1560-4 [8177245.001]
  • [Cites] Clin Exp Immunol. 1994 May;96(2):297-302 [8187337.001]
  • [Cites] Am J Hematol. 1994 Aug;46(4):375-6 [8037200.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1216-9 [8049436.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):300-1 [7612497.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Blood. 1996 May 1;87(9):3869-76 [8611714.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):109-13 [9111592.001]
  • [Cites] Hematol J. 2004;5(6):546-7 [15570303.001]
  • [Cites] J Thromb Haemost. 2005 Jan;3(1):74-8 [15634268.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2007-15 [15284121.001]
  • [Cites] Autoimmun Rev. 2005 Jun;4(5):264-9 [15990072.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2018-25 [15914560.001]
  • [Cites] Curr Opin Immunol. 2005 Dec;17(6):638-42 [16209918.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):109-14 [16043218.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):230-9 [16616070.001]
  • [Cites] Blood. 2006 Jul 1;108(1):292-6 [16527887.001]
  • [Cites] Am J Hematol. 2006 Aug;81(8):598-602 [16823816.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1689-92 [17145607.001]
  • [Cites] Cancer Res. 2009 Jul 1;69(13):5424-32 [19549911.001]
  • [Cites] Leuk Res. 2009 Nov;33(11):1452-3 [19632721.001]
  • [Cites] Leuk Lymphoma. 2009 Aug;50(8):1261-8 [19811329.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2701-15 [9326237.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):442-7 [10086776.001]
  • (PMID = 20620970.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097274-01; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / P50 CA097274-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 84
  • [Other-IDs] NLM/ NIHMS174960; NLM/ PMC2909690
  •  go-up   go-down


Advertisement
4. Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R: Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie; 2009 Oct;32(10):586-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary manifestation of small lymphocytic lymphoma in the prostate.
  • BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.
  • CONCLUSIONS: Lymphocytic infiltration of the prostate associated with obstructive symptoms is rare but can already occur in very early disease.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]
  • (PMID = 19816076.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


5. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Becker N, Benavente Y, Boffetta P, Brennan P, Butterbach K, Cocco P, Foretova L, Maynadié M, de Sanjosé S, Staines A, Spinelli JJ, Achenbach SJ, Call TG, Camp NJ, Glenn M, Caporaso NE, Cerhan JR, Cunningham JM, Goldin LR, Hanson CA, Kay NE, Lanasa MC, Leis JF, Marti GE, Rabe KG, Rassenti LZ, Spector LG, Strom SS, Vachon CM, Weinberg JB, Holly EA, Chanock S, Smith MT, Bracci PM, Skibola CF: Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet; 2010 Aug;42(8):661-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.
  • To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study.
  • We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 x 10(-29) and rs7755224, combined P = 2.00 x 10(-19); r(2) = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility.
  • We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 x 10(-9)).
  • [MeSH-major] Genome-Wide Association Study. Lymphoma, Follicular / genetics
  • [MeSH-minor] Disease Susceptibility. Genetic Variation. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Major Histocompatibility Complex. Risk Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunogenet. 1999 Dec;26(6):389-92 [10583459.001]
  • [Cites] Tissue Antigens. 2003 Oct;62(4):296-307 [12974796.001]
  • [Cites] Hematology. 2004 Apr;9(2):139-45 [15203870.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1166-72 [16998491.001]
  • [Cites] Leukemia. 2010 May;24(5):1055-8 [20147981.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • [Cites] Int J Hematol. 2008 Mar;87(2):203-9 [18301962.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • (PMID = 20639881.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CA / R01 CA087014-01A1; United States / NCI NIH HHS / CA / CA89745; United States / NCI NIH HHS / PC / N01 PC067010; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / PC / N01 PC067008; United States / NCI NIH HHS / CA / CA122663; United States / NCI NIH HHS / CA / R01 CA122663; United States / NCI NIH HHS / CA / CA104682; United States / NCI NIH HHS / CA / R01 CA062006; United States / NCI NIH HHS / PC / N01 PC065064; United States / NCI NIH HHS / CA / R01 CA104682; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / R01 CA087014; United States / NCI NIH HHS / CA / R01 CA045614; United States / NCI NIH HHS / CA / R03 CA089745-01; United States / NCI NIH HHS / CA / U01 CA118444; United States / NCI NIH HHS / CA / R03 CA089745
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS216166; NLM/ PMC2913472
  •  go-up   go-down


6. Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, Keating MJ, Medeiros LJ: Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol; 2005 Apr;123(4):594-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.
  • We studied the clinicopathologic, immunophenotypic, and cytogenetic features of 26 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) associated with serum IgM paraprotein.
  • Neoplasms in bone marrow were composed of small round lymphocytes arranged in nodular (n = 6), diffuse (n = 5), interstitial (n = 5), or mixed (n = 10) patterns.
  • The overall survival of this group (median follow-up, 24 months) was not significantly different from that for an age-, sex-and stage-matched group of 52 CLL/SLL patients without IgM paraprotein (P = .60).
  • [MeSH-major] Immunoglobulin M / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Paraproteins / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743747.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Paraproteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


7. Damle RN, Calissano C, Chiorazzi N: Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol; 2010 Mar;23(1):33-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.
  • B cell-type chronic lymphocytic leukaemia (CLL) has long been considered a disease of resting lymphocytes.
  • However, cell surface and intracellular phenotypes suggest that most CLL cells are activated cells, although only a small subset progresses beyond the G1 stage of the cell cycle.
  • In addition, traditional teaching says that CLL cells divide rarely, and therefore the build-up of leukaemic cells is due to an inherent defect in cell death.
  • However, in vivo labelling of CLL cells indicates a much more active rate of cell birth than originally estimated, suggesting that CLL is a dynamic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3741-8 [12393602.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1087-93 [12393552.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1262-9 [12406914.001]
  • [Cites] Annu Rev Immunol. 2003;21:841-94 [12615894.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):383-9 [12688308.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):380-8 [14616995.001]
  • [Cites] Blood. 2004 Jan 15;103(2):375-82 [14504108.001]
  • [Cites] Electrophoresis. 2004 Jun;25(10-11):1530-5 [15188237.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Blood. 1967 Apr;29(4):Suppl:594-607 [5336834.001]
  • [Cites] Blood. 1968 Mar;31(3):277-91 [5640626.001]
  • [Cites] Blood. 1973 Oct;42(4):623-36 [4778708.001]
  • [Cites] J Immunol. 1979 Mar;122(3):1087-90 [376702.001]
  • [Cites] J Clin Invest. 1979 Nov;64(5):1141-8 [159311.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3218-9; author reply 3219-20 [16809747.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4634-41 [17008705.001]
  • [Cites] Leukemia. 2007 Jan;21(1):110-20 [17024114.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1660-8 [17038534.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5390-8 [17327405.001]
  • [Cites] Leuk Res. 2007 Jun;31(6):773-7 [16970987.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3352-9 [17684154.001]
  • [Cites] Autoimmun Rev. 2007 Dec;7(2):102-8 [18035318.001]
  • [Cites] Blood. 2008 May 15;111(10):5173-81 [18326821.001]
  • [Cites] Blood. 2008 Jul 1;112(1):188-95 [18292287.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2427-37 [18551193.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1923-30 [18577710.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):240-7 [18710389.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10137-44 [19074880.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):788-801 [19452318.001]
  • [Cites] Blood. 2009 Nov 26;114(23):4832-42 [19789386.001]
  • [Cites] Blood. 2010 Jan 14;115(2):296-305 [19897574.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2036-41 [15514014.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):275-81 [15886117.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1018-24 [15800671.001]
  • [Cites] Eur J Haematol. 2005 Jul;75(1):34-40 [15946308.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1275-85 [16109604.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):939-45 [16189522.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6143-54 [16237111.001]
  • [Cites] Hum Pathol. 2006 Feb;37(2):152-9 [16426914.001]
  • [Cites] Exp Cell Res. 2000 Jun 15;257(2):231-7 [10837136.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):676-84 [11063931.001]
  • [Cites] Blood. 2001 May 1;97(9):2777-83 [11313271.001]
  • [Cites] Haematologica. 2001 Sep;86(9):995-6 [11532633.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] Anal Biochem. 2001 Nov 15;298(2):189-95 [11700973.001]
  • [Cites] Scand J Haematol. 1980 Feb;24(2):169-73 [7375818.001]
  • [Cites] Leuk Res. 1983;7(1):1-10 [6834882.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):328-32 [3891066.001]
  • [Cites] Br J Haematol. 1986 Mar;62(3):567-75 [3954968.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2712-6 [3677006.001]
  • [Cites] Am J Physiol. 1992 Nov;263(5 Pt 1):E988-1001 [1443132.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):925-35 [7681471.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):329-39 [8006591.001]
  • [Cites] Blood Cells. 1993;19(3):591-6; discussion 597-9 [8018941.001]
  • [Cites] Immunol Today. 1994 Jun;15(6):288-94 [7520700.001]
  • [Cites] Histopathology. 1994 May;24(5):445-51 [8088716.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):381-8 [7729951.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3556-65 [7540066.001]
  • [Cites] J Immunol. 1997 Feb 1;158(3):1482-9 [9013995.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4940-7 [9354461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10827-32 [9380719.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3140-8 [9399961.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2689-97 [9531577.001]
  • [Cites] Immunol Rev. 1998 Apr;162:261-80 [9602370.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6312-5 [10352241.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):662-8 [10468854.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Lab Clin Med. 1961 Nov;58:751-62 [14494938.001]
  • [Cites] Haematologica. 2001 Dec;86(12):1296-304 [11726322.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Leukemia. 2002 Feb;16(2):178-85 [11840283.001]
  • [Cites] Histopathology. 2002 Jan;40(1):2-11 [11903593.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4087-93 [12010811.001]
  • (PMID = 20620969.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081554-06A1; United States / NCI NIH HHS / CA / R01 CA081554; United States / NCI NIH HHS / CA / R01 CA081554-06A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 82
  • [Other-IDs] NLM/ NIHMS182114; NLM/ PMC2921990
  •  go-up   go-down


8. Dillman RO, Schreeder MT, Hon JK, Connelly EF, DePriest C, Cutter K: Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm; 2007 Apr;22(2):185-93
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • We conducted a multicenter, community-based phase II trial of PCR biochemotherapy (pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2) every 3 weeks for up to 6 cycles in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • The median age of patients was 69 years; 11 patients were over age 70, and 71% had Rai stage III or IV disease.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Cyclophosphamide / therapeutic use. Delivery of Health Care. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Pentostatin / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7 [17979574.001]
  • (PMID = 17600465.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Membrane Glycoproteins; 143891-49-0 / TI 1 protein, Mustela vison; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Struski S, Leymarie V, Helias C, Falkenrodt A, Fohrer C, Audhuy B, Lioure B, Moskovtchenko P, Mazurier I, Galoisy AC, Gervais C, Mauvieux L, Herbrecht R, Bergerat JP, Lessard M: [A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies]. Pathol Biol (Paris); 2007 Feb;55(1):59-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies].
  • [Transliterated title] Etude cytologique, immunophénotypique et cytogénétique d'une série de 136 cas consécutifs d'hémopathies lymphoïdes chroniques à cellules B matures.
  • A cytological, immunophenotypical and cytogenetical study of 136 chronic B-cell proliferations (93 CLL, 43 B-cell lymphomas) was led in order to precise diagnosis and to characterize and appreciate chromosomal rearrangements.
  • In this series, mainly selected on blood lymphocytosis criteria, B-CLL were twice more frequent than small B-cell lymphomas.
  • The frequency of clonal abnormalities (CC and FISH) was 74.8% for this series, with 74.4% for lymphomas and 75.3% for CLL, mainly of Binet stage A (69 A, 13 B, 1 C, 10 unspecified).
  • In CLL, 13q14 cryptic deletions and translocations were widely majority, 14q32 translocations and trisomy 12 being predominant in lymphoma series.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690228.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B: Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma. Arch Ophthalmol; 2007 Dec;125(12):1663-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.
  • OBJECTIVE: To determine the stage at initial examination and the prevalence of systemic involvement in patients with orbital and ocular adnexal lymphoma.
  • METHODS: The medical records of all patients with orbital and ocular adnexal lymphoma treated in a recent 7-year period were reviewed for stage at initial examination, highest stage during the follow-up period, and recurrence-free survival.
  • Nineteen patients had mucosa-associated lymphoid tissue, 9 had follicular, 9 had diffuse large-cell, 3 had mantle cell, 2 had small lymphocytic, and 1 had large T-cell lymphoma.
  • Lymphoma stage at diagnosis was IE in 18 patients, II in 6, and IV in 19.
  • Six of 19 patients with mucosa-associated lymphoid tissue, 7 of 9 patients with follicular, 6 of 9 patients with diffuse large-cell, and 3 of 3 patients with mantle cell lymphoma had non-stage IE disease at initial examination.
  • CONCLUSIONS: Extraorbital involvement is present at diagnosis in more than half of patients with orbital and ocular adnexal lymphoma and warrants extensive systemic workup at diagnosis, continued surveillance, and consideration of systemic therapy.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Lymphoma / pathology. Orbital Neoplasms / pathology

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071119.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gallium Radioisotopes
  •  go-up   go-down


11. Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res; 2010 Apr;34(4):454-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
  • In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance.
  • EXPERIMENTAL DESIGN: We applied real-time PCR method to assess the mRNA expression of equilibrative and concentrative nucleoside transporter (hENT1, hCNT1), deoxycytidine and deoxyguanosine kinase (dCK, dGK), 5'-nucleotidase (5'-NT), ribonucleotide reductase catalytic and regulatory (RR1, RR2) subunits in bone marrow cells from 32 patients with Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) who received 2CdA-based chemotherapy.
  • No significant correlation between these genes expression and age, stage of disease was found.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cladribine / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Membrane Transport Proteins / genetics. Waldenstrom Macroglobulinemia / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19647871.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


12. Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD: A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol; 2005 Apr;28(2):169-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
  • This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma.
  • This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage.
  • Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803012.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Zhang YN, Zhou XG, Zhang SH, Zheng YY, Liu WH: [Nodal marginal zone B-cell lymphoma: a clinicopathologic study of 10 cases]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):529-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nodal marginal zone B-cell lymphoma: a clinicopathologic study of 10 cases].
  • OBJECTIVE: To study the morphologic features, immunophenotype, differential diagnosis and prognosis of nodal marginal zone B-cell lymphoma (NMZL).
  • Amongst the 7 cases with follow-up information available, most (6/7) were in advanced clinical stage (stage II to III).
  • The lymphoma was composed predominantly of atypical lymphoid cells resembling centrocytes (7/10).
  • A predominance of monocytoid B-cell (2/10) or small lymphocytic (1/10) morphology was rare.
  • Differential diagnosis includes lymphoplasmacytic lymphoma, lymph node involvement by extranodal marginal zone B-cell lymphoma and T-zone hyperplasia.
  • The clinical stage is often high at presentation, with systemic dissemination.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980100.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


14. Chen ZY, Zhou XY, Zhang TM, Hong XN, Yin JL, Hu XC, Shi DR: [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):183-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
  • OBJECTIVE: To explore the feasibility of semi-nested PCR technique for detection of immunoglobulin heavy chain (IgH) clonal rearrangement in bone marrow of B-cell lymphoma patient and to further evaluate its clinicopathological value.
  • METHODS: Gene clonal rearrangement of IgH was detected by semi-nested PCR using primers of FR2 & FR3A in 105 bone marrow samples of patients with B-cell lymphoma.
  • RESULTS: Among 105 cases of B-cell lymphoma, bone marrow involvement was detected by PCR technique in 48 cases (45.7%), while only 22 cases (21.0%) were detected by bone marrow cytological analysis.
  • The incidence of bone marrow involvement at the time of initial diagnosis detected by PCR technique was 30.8% for diffuse large B cell lymphoma (DLBCL), 25.0% for follicular lymphoma (FL), and 100.0% for small lymphocytic lymphoma (SLL), respectively.
  • Bone marrow involvement detected by PCR detection correlated with Ann Arbor stage.
  • Rate of clonal IgH gene rearrangement by PCR in early B-cell lymphoma was lower than that in advanced stage B-cell lymphoma patients (P = 0.02).
  • CONCLUSION: Semi-nested PCR analysis may be an effective method for detection of abnormalities in bone marrow in patients with B-cell lymphoma and is superior to cytomorphology.
  • The positive rate in patients with advanced Ann Arbor stage is higher than that in patients with early Ann Arbor stage, and patients with PCR negative result have more chances to achieved CR after treatment.
  • [MeSH-major] Bone Marrow / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Immunoglobulin Heavy Chains / genetics. Lymphoma, Large B-Cell, Diffuse / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy / methods. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615255.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


15. Motoi N, Ozawa Y: Malignant T-cell lymphoma of the thyroid gland associated with Hashimoto's thyroiditis. Pathol Int; 2005 Jul;55(7):425-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant T-cell lymphoma of the thyroid gland associated with Hashimoto's thyroiditis.
  • Reported herein is a rare case of malignant T-cell lymphoma of the thyroid gland that developed in a 71-year-old woman with a past history of chronic thyroiditis.
  • A diagnosis of suspicious malignant lymphoma of the thyroid gland accompanied by Hashimoto's thyroiditis was made, and a total thyroidectomy was performed.
  • Histological examination revealed diffuse small lymphocytic infiltration in the thyroid gland associated with Hashimoto's thyroiditis.
  • Immunohistochemical examination showed that the small lymphocytes were positive for T-cell markers with CD4 predominance.
  • Southern blot analysis of tumor specimens revealed a monoclonal T-cell receptor gene rearrangement.
  • Peripheral T-cell lymphoma was diagnosed.
  • No adjuvant therapy was performed because of the tumor stage and its subtype.
  • The present case suggests that Hashimoto's thyroiditis might play an important role in the carcinogenesis of thyroid lymphoma not only of B-cell lineage but also of T-cell lineage.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Thyroid Neoplasms / pathology. Thyroiditis, Autoimmune / pathology

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982218.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD3; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


16. Chuang SS, Liao YL, Liou CP, Wiggins ML, Ye H, Du MQ, Isaacson PG, Chang CC: Chronic lymphocytic leukemia with paraimmunoblastic transformation - with comparative genomic hybridization and review of the literature. Pathol Res Pract; 2010 Apr 15;206(4):276-81
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia with paraimmunoblastic transformation - with comparative genomic hybridization and review of the literature.
  • Richter's transformation (RT) is the development of a high-grade lymphoma in patients with B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • A 78-year-old Taiwanese male had Rai stage 1 and Binet stage B CLL/SLL involving skin, peripheral blood (PB), and bone marrow (BM) with paraimmunoblastic transformation in the lymph node.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymph Nodes / pathology
  • [MeSH-minor] Aged. B-Lymphocytes / pathology. Comparative Genomic Hybridization. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Staging. Trisomy / genetics. Trisomy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19433347.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


17. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):258-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
  • BACKGROUND: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database.
  • A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease.
  • According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma.
  • All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (>or= 3 previous treatments), and 2 had had autologous stem cell transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709661.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


18. Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, Qian S, Xu W: The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2007 Sep;48(9):1785-92
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) is characterized by the relentless accumulation of monoclonal B cells with the appearance of small mature lymphocytes and a characteristic CD5 and CD19 co-expression immunophenotype.
  • The expression levels of CLLU1 were significantly increased in B + C CLL patients at Binet stage compared with those at Binet stage A (P = 0.005).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1665-6 [17786698.001]
  • (PMID = 17786715.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLLU1 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Neoplasm Proteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


19. Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R: Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma; 2006 May;47(5):827-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study.
  • The objective of this study was to assess the incidence and the clinical significance of Epstein-Barr virus (EBV) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • EBERs were observed in sporadic granulocytes alone or in addition to its presence in lymphocytes in nine of the 12 EBV-positive patients.
  • EBERs were detected less frequently in patients with Rai stage 0 - 1 disease (20%) compared with Rai stage 2 - 4 (66%; p = 0.008).
  • Despite the small number of patients tested, discernable EBERs were significantly more common in individuals with more advanced Rai stage and there was a trend toward shorter survival in patients in whom EBV EBERs were discerned.
  • [MeSH-major] Herpesvirus 4, Human. Leukemia, Lymphocytic, Chronic, B-Cell / virology


20. Magro CM, Dyrsen ME: Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol; 2008 Nov;35(11):1040-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
  • BACKGROUND: Cutaneous lymphocyte-associated antigen (CLA) is expressed in resident cutaneous T lymphocytes, high endothelial venules, peripheral monocytes, granulocytes and a small percentage of memory B cells.
  • It has been postulated to be an important factor in homing of lymphocytes to the skin because of its function as a ligand for E-selectin expressed on cutaneous endothelial cells.
  • DESIGN: We investigated the expression of CLA using the HECA-452 antibody on paraffin-embedded, formalin-fixed tissue in a variety of reactive, neoplastic and preneoplastic cutaneous lymphoid infiltrates of T- and B-cell derivation.
  • High levels of CLA expression were seen in epidermotropic T-cell dyscrasias and epidermotropic T-cell lymphomas including mycosis fungoides (MF) and adult T-cell leukemia/lymphoma (ATCLL).
  • A loss of CLA in tumors normally positive for CLA was a feature of disease progression best exemplified by tumor-stage MF and acute ATCLL.
  • There was a lack of CLA expression in those lymphocytic infiltrates manifesting subcutaneous localization including lupus profundus, panniculitis-like T-cell lymphoma and atypical lymphocytic lobular panniculitis.
  • CLA expression was not only observed in primary cutaneous anaplastic large cell lymphoma but also seen in cases of nodal anaplastic large cell lymphoma secondarily involving the skin and was negative in cases of nodal anaplastic large cell lymphoma without any established skin involvement.
  • CLA was negative in the majority of B-cell lymphomas.
  • CONCLUSIONS: CLA plays a role in the pattern of T-cell lymphocyte migration in the skin and subcutis in both reactive and neoplastic states.
  • An alteration in the expression of this marker, whether it is in the context of the acquisition of expression in a cell that is normally CLA negative or its loss of expression, may define a key event in determining cutaneous and extracutaneous hematopoietic cell distribution.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Dermatitis / immunology. Lymphoma, B-Cell / immunology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18681860.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Szekanecz E, Szamosi S, Gergely L, Keszthelyi P, Szekanecz Z, Szucs G: Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol; 2008 Sep;27(9):1163-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis.
  • Recent results suggest that B cells may have multiple pathogenic roles in systemic sclerosis (SSc) and there may be increased incidence of B cell lymphomas in SSc.
  • During this follow-up period, there were three SSc patients, who eventually developed B cell lymphoma.
  • B cell chronic lymphocytic leukemia (B-CLL) with Zap70 expression (Rai I stage) developed 2 years after the onset of SSc.
  • Twenty-one months after disease onset, a chronic small lymphocytic B cell non-Hodgkin's lymphoma was diagnosed from retroperitoneal lymph nodes.
  • She also developed Zap70-positive B-CLL, stage Rai I 9 months after the onset of SSc.
  • Thus, there were three cases of B cell lymphoma among our 218 SSc patients (1.38%).
  • The association of scleroderma and non-Hodgkin's lymphoma may be a rather uncommon feature; however, the incidence of lymphoma among Hungarian SSc patients may be 1.9-2.5 times higher than that in the general population.
  • In our three patients, B cell lymphoma developed within 2 years after the onset of SSc.
  • Altered B cell function implicated in the pathogenesis of SSc may lead to the development of lymphoid malignancies.
  • [MeSH-major] Lymphoma, B-Cell / complications

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatol Int. 2002 Nov;22(6):233-7 [12426661.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2740-50 [16142737.001]
  • [Cites] Curr Opin Rheumatol. 2005 Nov;17(6):746-51 [16224253.001]
  • [Cites] Joint Bone Spine. 2006 Jan;73(1):105-8 [15994110.001]
  • [Cites] Acta Derm Venereol. 1985;65(6):521-5 [2420117.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):43-8 [16501834.001]
  • [Cites] Ann Rheum Dis. 1993 Jul;52(7):531-3 [8346981.001]
  • [Cites] Arthritis Rheum. 1985 Dec;28(12):1336-40 [4084328.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):103-6 [14662423.001]
  • (PMID = 18500435.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Nogová L, Rudiger T, Engert A: Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2006;:266-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
  • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) differs in histological and clinical presentation from classical Hodgkin lymphoma (cHL).
  • The typical morphologic signs of NLPHL are atypical "lymphocytic and histiocytic" (L&H) cells, which are surrounded by a non-neoplastic nodular background of small lymphocytes of B-cell origin.
  • Treatment of NLPHL patients using standard Hodgkin lymphoma (HL) protocols leads to complete remission (CR) in more than 95% of patients.
  • Survival and freedom from treatment failure (FFTF) are worse in advanced-stage patients than in early-stage patients.
  • In contrast, patients with early-stage NLPHL without risk factors can be sufficiently treated with reduced intensity programs having less severe adverse effects.
  • As a result, treatment of early NLPHL is less clearly defined, including radiotherapy in extended field (EF) or involved field (IF) technique, combined modality treatment, and, more recently, monoclonal antibody rituximab.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17124071.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


23. Wood L, Robinson R, Gavine L, Juritz J, Jacobs P: A single unit lymphoma experience: outcome in a Cape Town academic centre. Transfus Apher Sci; 2007 Aug;37(1):93-102
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single unit lymphoma experience: outcome in a Cape Town academic centre.
  • Fifty-seven percent were stage I or II and 21% had nodal disease above and below the diaphragm whilst in the remainder cells were present in the circulation and this included the subset of chronic lymphocytic leukaemia -- small lymphocytic lymphoma.
  • Analysed by disease category Hodgkin lymphoma (n=17) when managed according to the German Study Group protocols and hairy cell leukaemia (n=10) treated with two chlorodeoxyadenosine -- both had a stable plateau in excess of 90%.
  • Curves for the aggressive or diffuse large B-cell lymphoma (n=44) fell initially to 48%, but relapse continued in stages III and IV to the current level of 18% when receiving cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone on the 21-day schedule.
  • Chronic lymphocytic leukaemia -- small lymphocytic lymphoma (n=58) were initially given pulsed chlorambucil and sustained response was over 90% with low bulk, but declined to reach 30% as prognostic score rose.
  • [MeSH-major] Hospitals, Private. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma / mortality. Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931976.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Graff-Baker A, Roman SA, Thomas DC, Udelsman R, Sosa JA: Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. Surgery; 2009 Dec;146(6):1105-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases.
  • BACKGROUND: There is a paucity of data regarding prognosis of primary thyroid lymphoma (PTL), with only case reports and institutional series reported.
  • Overall, 98% had non-Hodgkin's lymphoma; 68% had diffuse large B-cell, 10% follicular, 10% marginal zone, and 3% small lymphocytic.
  • A total of 88% had stage I-II disease.
  • On bivariate analysis, older age, single marital status, stage II-IV disease, histology (large B-cell, follicular, or other non-Hodgkin's), earlier year of diagnosis, lack of prior malignancies, and no radiation/surgery predicted worse survival.
  • Age >or=80 years, advanced stage, no radiation/surgery, and large B-cell or follicular histology predicted worse prognosis in multivariate analysis.
  • CONCLUSION: Older age, advanced stage, histologic subtype, and lack of radiation/surgical treatment are associated with worse survival.
  • Thyroid resection offers benefit only for patients with stage I disease.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, B-Cell, Marginal Zone / mortality. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / mortality. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. United States / epidemiology

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958938.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Choo SP, Lim ST, Wong EH, Tao M: Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy. Onkologie; 2006 Feb;29(1-2):14-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.
  • PURPOSE: This paper is to determine the clinicopathological features and outcome of patients with breast lymphoma seen at a single institution.
  • PATIENTS AND METHODS: We have reviewed data on 14 patients with breast lymphoma seen at our institution from 1990 to 2003.
  • Diffuse large B-cell lymphoma (DLBCL) was observed in 9 cases, while follicular, Burkitt's, small lymphocytic, MALT and T-cell lymphoma were observed in 1 case each.
  • 5 patients (35.7%) had stage IE disease, 6 patients (42.9%) had stage IIE disease and 3 patients (21.4%) had stage IV disease.
  • Standard CHOP with or without rituximab was given to all patients with aggressive breast lymphoma (n = 10), while 1 patient with Burkitt's lymphoma received a CHOP-based regimen.
  • The 3-year actuarial survival estimate among all 11 patients with aggressive breast lymphoma was 73%.
  • The actuarial 3-year overall survival (OS) estimate for the entire cohort of 14 patients was 76.9%.
  • CONCLUSION: Our results indicate that breast lymphoma is not associated with an inferior outcome when treated with standard CHOP-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Lymphoma / drug therapy. Lymphoma / mortality

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514249.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A: [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. Bull Cancer; 2007 Oct;94(10):902-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
  • [Transliterated title] Caractéristiques thérapeutiques et évolutives des lymphomes folliculaires du Noir africain: expérience de la Côte d'Ivoire.
  • We reported in this study a treatment results about 36 Africans patients with follicular lymphoma.
  • Clinical characteristics of patients are mainly represented by advance stage with 70% of stage III and IV of Ann Arbor classification.
  • Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27.78 and 22.22%.
  • Indeed, the follicular lymphomas constituted by large cells and mixed cells had higher rate of complete remission with respectively 46.67% and 40% in relation with those of small cells with a higher failure rate.
  • The short survival delay time of our patients didn't permit time to observe transformation case in diffuse large cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cote d'Ivoire. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964984.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP-B protocol; COP protocol 2
  •  go-up   go-down


27. Ng M, Wirth A, Ryan G, MacManus M, Davis S: Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma. Australas Radiol; 2006 Jun;50(3):222-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma.
  • Low-dose radiotherapy over the last decade has been reported to provide effective palliation for patients with low-grade non-Hodgkin's lymphoma.
  • In this retrospective case series of 10 patients, we report our early experience using low-dose radiotherapy (usually 2 x 2 Gy) for patients with advanced-stage follicular, mucosal associated lymphoid tissue, mantle cell and small lymphocytic lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Palliative Care / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732818.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Martinez A, Pittaluga S, Rudelius M, Davies-Hill T, Sebasigari D, Fountaine TJ, Hewitt S, Jaffe ES, Raffeld M: Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker. Am J Surg Pathol; 2008 Aug;32(8):1190-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.
  • To assess the role of interferon regulatory factor (IRF) 8 in B-cell development and lymphomagenesis, we studied its expression in reactive lymphoid tissues, its relationship to other B-cell transcription factors, and its expression in a series of 232 B-cell tumors and 30 cell lines representing a variety of B-cell developmental stages.
  • We found that although IRF8 was detectable in most reactive B-cells, its expression levels differed with developmental stage.
  • IRF8 was coexpressed with PAX-5, Pu.1, and B-cell lymphoma (BCL)-6, and similar to BCL-6, was absent from the small population of IRF4-positive germinal center B cells thought to be committed to postgerminal center developmental programs.
  • Similarly, IRF8 was most strongly expressed in lymphomas of germinal center origin with lower levels present in mantle cell lymphomas, chronic lymphocytic leukemia, and marginal zone lymphomas, and no expression observed in plasmacytic/plasmablastic neoplasms.
  • These results suggest an important role for IRF8 during germinal center B-cell development and in related lymphomas, and provide a new diagnostic marker helpful in distinguishing B-cell non-Hodgkin lymphoma subtypes.
  • [MeSH-major] B-Lymphocytes / metabolism. Biomarkers, Tumor / metabolism. Germinal Center / metabolism. Interferon Regulatory Factors / metabolism. Lymphoma, B-Cell / metabolism
  • [MeSH-minor] B-Cell-Specific Activator Protein / metabolism. Cell Line, Tumor. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, B-Cell, Marginal Zone / metabolism. Lymphoma, Mantle-Cell / metabolism. Palatine Tonsil / chemistry. Plasma Cells / metabolism. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580679.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / PAX5 protein, human; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / interferon regulatory factor-4; 0 / interferon regulatory factor-8; 0 / proto-oncogene protein Spi-1
  •  go-up   go-down


29. Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U: Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk Lymphoma; 2007 Jun;48(6):1139-49
Genetic Alliance. consumer health - Pure red cell aplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas.
  • We analyzed 108 cases of non-CLL non-Hodgkin lymphoma (NHL) associated with autoimmune hemolytic anemia (AIHA) (+/- pure red cell aplasia (PRCA)) or Evans' syndrome.
  • The number of cases in various NHL subtypes was small (n = 6-25).
  • Nevertheless, interesting and sometimes unexpected differences in sex prevalence, temporal relationship between onset of lymphoma and AIHA, stage of lymphoma, relative frequency of warm antibody-AIHA (WA-AIHA) and cold antibody (CA-AIHA), association with PRCA and response of AIHA to treatments were noted for various lymphoma entities.
  • WA-AIHA was more frequent in B-cell lymphomas, while CA-AIHA and PRCA predominantly occurred in T-cell lymphomas.
  • Anti-lymphoma treatment seemed to be more effective against AIHA than conventional therapy with steroids or immunoglobulin.
  • Although generated by a literature survey, this compilation of data indicates a complex relation of lymphoma and AIHA and warrants more attention and specific studies.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Lymphoma, Non-Hodgkin / complications. Purpura, Thrombocytopenic, Idiopathic / etiology. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] Humans. Leukemia, Hairy Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, B-Cell / complications. Lymphoma, Follicular / complications. Lymphoma, Mantle-Cell / complications. Lymphoma, T-Cell, Peripheral / complications. Multiple Myeloma / complications. Prognosis. Risk Factors. Syndrome

  • Genetic Alliance. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577777.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


30. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer; 2008 Jun;50(6):1181-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
  • BACKGROUND: ABT-263 is a potent (K(i) < 1 nM) small-molecule BH3 mimetic that inhibits the antiapoptotic proteins Bcl-2, Bcl-x(L) and Bcl-w.
  • The structurally related Bcl-2 inhibitor ABT-737 exhibits single-agent preclinical activity against lymphoma, small-cell lung carcinoma, and chronic lymphocytic leukemia and displays synergistic cytotoxicity with chemotherapeutics and radiation.
  • METHODS: ABT-263 was tested at concentrations ranging from 1.0 nM to 10.0 microM using 23 cell lines from the PPTP in vitro panel and was tested in 44 xenograft models representing nine distinct histologies using daily gavage administration of ABT-263 (100 mg/kg) or vehicle for 21 days.
  • RESULTS: ABT-263 was active against approximately one-half of the cell lines of the PPTP in vitro panel.
  • CONCLUSIONS: ABT-263 demonstrated in vitro activity against a range of cell lines, with the ALL cell lines showing the greatest sensitivity.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Child. Female. Humans. Mice. Mice, Inbred Strains. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18085673.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfonamides; XKJ5VVK2WD / navitoclax
  •  go-up   go-down


31. Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB: [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi; 2007 Dec;46(12):996-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
  • OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).
  • The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died.
  • In the remaining 7 patients it occurred an early stage after HSCT (day 32-78).
  • One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor lymphocyte infusion.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478915.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


32. Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR: Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. J Chemother; 2009 Aug;21(4):434-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.
  • Patients had an ECOG performance of 0-2, and Stage III and IV disease.
  • This program is well tolerated with a high CR rate, and may serve as a basis for future trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622463.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


33. Kopp KL, Kauczok CS, Lauenborg B, Krejsgaard T, Eriksen KW, Zhang Q, Wasik MA, Geisler C, Ralfkiaer E, Becker JC, Ødum N, Woetmann A: COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia; 2010 Jun;24(6):1179-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF).
  • In this study we show that COX-2 is ectopically expressed in malignant T-cell lines from patients with cutaneous T-cell lymphoma (CTCL) as well as in situ in lymphocytic cells in 21 out of 22 patients suffering from mycosis fungoides (MF) in plaque or tumor stage.
  • COX-2 is not expressed in lymphocytes of 11 patients with patch-stage MF, whereas sporadic COX-2 staining of stromal cells is observed in the majority of patients.
  • These cells express prostaglandin receptors EP3 and EP4 and the receptor antagonist as well as small interfering RNA (siRNA) directed against COX-2, and specific COX-2 inhibitors strongly reduce their spontaneous proliferation.
  • In conclusion, our data indicate that COX-2 mediated PGE(2) exerts an effect as a tumor growth factor in MF.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Lymphoma, T-Cell, Cutaneous / metabolism. Mycosis Fungoides / metabolism. Prostaglandins E / pharmacology. Skin Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Proliferation. Cyclooxygenase 2 Inhibitors / pharmacology. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Receptors, Prostaglandin E / metabolism. Receptors, Prostaglandin E, EP3 Subtype. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428208.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / PTGER3 protein, human; 0 / Prostaglandins E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP3 Subtype; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


34. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


35. Wahner-Roedler DL, Kyle RA: Heavy chain diseases. Best Pract Res Clin Haematol; 2005;18(4):729-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heavy chain diseases (HCDs) are rare B-cell lymphoplasma-cell proliferative disorders characterized by production of truncated monoclonal immunoglobulin heavy chains without associated light chains.
  • HCDs can be thought of as variant types of non-Hodgkin lymphoma: alpha-HCD presents as an extranodal marginal-zone lymphoma of mucosa-associated lymph-node tissue, gamma-HCD as lymphoplasmacytoid non-Hodgkin lymphoma, and mu-HCD as small lymphocytic non-Hodgkin lymphoma or chronic lymphocytic leukemia.
  • Prognosis is variable, and no standardized effective treatment programs are available except for alpha-HCD, which in its early stage may respond to antibiotics.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026747.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 38
  •  go-up   go-down


36. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I: Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther; 2009 Oct;8(10):2821-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with advanced breast cancer frequently develop bone metastases, and at this stage, the disease is considered incurable.
  • Tumors from the sequential treatment group also displayed increased levels of apoptosis, increased expression of bcl2-associated X protein, decreased expression of B-cell chronic lymphocytic leukemia/lymphoma 2, and activation of caspase 3, 8, and 9.
  • Zoledronic acid caused a small reduction in tumor volume, reduced tumor cell proliferation, and decreased expression of cyclins D1 and D3, compared with tumors from animals treated with saline or doxorubicin.
  • Doxorubicin had no effect on tumor growth, cell cycle, or apoptosis in vivo, but did cause increased accumulation of a bisphosphonate in MDA-MB-436 cells in vitro, suggesting that doxorubicin may affect subsequent uptake of zoledronic acid.
  • Our data are the first to show the specific molecular pathways by which sequential treatment with doxorubicin and zoledronic acid induce tumor cell apoptosis and inhibit proliferation in an in vivo model of breast tumor growth in bone.
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Bone and Bones / drug effects. Bone and Bones / pathology. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Models, Biological. Osteoclasts / drug effects. Osteoclasts / pathology. Xenograft Model Antitumor Assays






Advertisement